Mayor Angel M, Gomez Maria A, Fernandez Diana M, Rios-Olivares Eddy, Thomas James C, Hunter Robert F
Retrovirus Research Center, and Department of Microbiology, Universidad Central del Caribe, School of Medicine, Bayamón, Puerto Rico.
Am J Trop Med Hyg. 2006 Feb;74(2):239-45.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection is an important and frequent scenario, predominantly in injecting drug users (IDUs). The present study evaluated morbidity and mortality variation in HIV-infected patients with and without HCV co-infection. Co-infection prevalence was determined in 356 HIV-infected persons. Their clinical manifestations, laboratory findings, risk factors, HIV therapies, and mortality rates were evaluated. The prevalence of HCV was 54% in the overall group and 81% in IDUs, with a predominance of HCV genotype 1. Mortality rates were similar in patients with and without co-infection; however, co-infected patients had significantly higher liver damage as a cause of mortality when compared with those who were not co-infected. The high prevalence of HCV and an emerging mortality from liver diseases showed the significance of this co-infection in the HIV epidemic. Primary and secondary prevention are necessary to reduce the expanding impact of HCV infection in HIV patients.
丙型肝炎病毒（HCV）与人类免疫缺陷病毒（HIV）合并感染是一种重要且常见的情况，主要发生在注射吸毒者（IDU）中。本研究评估了合并HCV感染和未合并HCV感染的HIV感染者的发病率和死亡率变化。在356名HIV感染者中确定了合并感染的患病率。评估了他们的临床表现、实验室检查结果、危险因素、HIV治疗方法及死亡率。总体人群中HCV患病率为54%，注射吸毒者中为81%，以HCV 1型为主。合并感染和未合并感染患者的死亡率相似；然而，与未合并感染的患者相比，合并感染患者因肝损伤导致的死亡率显著更高。HCV的高患病率以及肝病导致的死亡率不断上升，表明这种合并感染在HIV流行中具有重要意义。一级和二级预防对于减少HCV感染对HIV患者不断扩大的影响是必要的。
